New book on RNA Interference edited by Mouldy Sioud recently published
Mouldy Sioud from Department of Immunology at the Institute for Cancer Research is the editor of a new book published November 10th entitled "RNA Interference: Challenges and Therapeutic Opportunities". The book is included in the series "Methods in Molecular Biology, Vol. 1218" and provides readers with recent advances in siRNA design, delivery, targeting and methods to minimize siRNA's unwanted effects. Preclinical and clinical use of synthetic siRNAs, the roles of miRNAs in cancer and the promise of extracellular miRNAs for diagnosis are also covered in this meticulous collection, along with novel methods for identifying endogenous siRNAs and the annotation of small RNA transcriptomes.
These excellent chapters will assist researchers, clinicians, teachers and biotechnologists interested in the power of RNA-based therapies.
Written for the highly successful Methods in Molecular Biology series, chapters include the kind of detail and key implementation advice that ensures successful results in the laboratory.
Includes cutting-edge techniques in using RNA interference for therapeutic purposes
Provides step-by-step detail essential for reproducible results
Contains key notes and implementation advice from the experts
Published in major journals, first or last author from Oslo University Hospital.
Sohlberg E, Pfefferle A, Ask EH, Tschan-Plessl A, Jacobs B, Netskar H, Lorenz S, Kanaya M, Kosugi-Kanaya M, Meinke S, Mörtberg A, Höglund P, Sundin M, Carlsson G, Palmblad J, Malmberg KJ(2021) Perturbed NK Cell Homeostasis Associated with Disease Severity in Chronic Neutropenia Blood(in press) DOI 10.1182/blood.2021013233, PubMed 34699594
Munson MJ, Mathai BJ, Ng MYW, Trachsel-Moncho L, de la Ballina LR, Schultz SW, Aman Y, Lystad AH, Singh S, Singh S, Wesche J, Fang EF, Simonsen A(2021) GAK and PRKCD are positive regulators of PRKN-independent mitophagy Nat Commun, 12(1), 6101 DOI 10.1038/s41467-021-26331-7, PubMed 34671015
Schuppan D, Mäki M, Lundin KEA(2021) A Trial of a Transglutaminase 2 Inhibitor in Celiac Disease. Reply N Engl J Med, 385(16), e57 DOI 10.1056/NEJMc2112688, PubMed 34644485